Benign prostatic hyperplasia

Also known as: BPH · enlarged prostate · LUTS

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesNKF/AUA

Current

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026)

American Urological Association (AUA) · 2026

AUA's current guideline on evaluating and treating male lower urinary tract symptoms attributed to BPH, spanning initial work-up, non-procedural and combination medical therapy, and procedural options.

AUA lists the current version as the 2026 BPH guideline. source
The guideline is organised into sections on evaluation, follow-up, pre-procedural testing, non-procedural interventions, combination therapy, procedural therapies and special cases. source

Verify against original ↗

EuropeERA/EAU (global: KDIGO)

Current

EAU Guidelines on the Management of Non-neurogenic Male LUTS

European Association of Urology (EAU) · 2026

EAU's guideline on assessing and treating benign forms of male lower urinary tract symptoms, deliberately framed around LUTS and benign prostatic obstruction rather than the histological label BPH.

EAU explains it treats LUTS, not histological BPH, as the clinical focus, since it is benign prostatic obstruction that is treated when it causes symptoms. source
EAU states all chapters of the 2026 guideline were fully updated from the 2024 version. source

Verify against original ↗

US vs EU key differences

Framing differs at the level of the title: the European guideline is deliberately built around non-neurogenic male lower urinary tract symptoms rather than benign prostatic hyperplasia, treating benign prostatic obstruction as one cause among several. source
Because of that framing the EAU document also covers male urinary incontinence and detrusor underactivity alongside conservative and surgical treatment of obstruction, widening the differential beyond a prostate-centred model. source
Both sides are current: the EAU 2026 edition is a full update of the 2024 text following a complete literature search, and the American guideline is likewise a 2026 release, so this is a topic where US and European guidance are unusually well synchronised in time. source

What changed recently

US2021 guideline with 2023 amendment → 20262026-05-07
The AUA replaced its 2021 BPH/LUTS guideline and the targeted 2023 amendment with a full rebuild published in 2026, based on a fresh systematic literature review. The document was restructured into three parts covering presentation and evaluation, medical management, and procedural or surgical management.
source ↗curation confidence 90%
EU2025 → 20262026-01-01
The 2026 EAU male LUTS guideline is a full revision of the 2025 edition: it adds a new section on prostate cancer within the diagnostic chapter, changes the strength rating for beta-3 agonists in conservative treatment, expands the surgical chapter with two new subsections emphasising alternative enucleation and ablative techniques, and adds guidance on male urinary incontinence, detrusor underactivity and voiding dysfunction in younger men.
source ↗

See the full update feed for changes across every system.